GENE ONLINE|News &
Opinion
Blog

2021-07-10| Asia-Pacific

Sparx Therapeutics to Build a Massive Manufacturing Plant in China for Multi-Specific Antibody Production

by Tyler Chen
Share To

Founded just around 3 years ago, a small Chicago biotech is prepared to build a huge production center in the Yangzhou Economic Zone, China, to increase manufacturing capacity for its antibody-drug pipelines.

On July 8th, Sparx Therapeutics announced the plan to establish a 1.2 million-square-foot plant in China and is estimated to begin operating at the end of 2022.

 

Increasing Capacity for Commercial Production

The new plant in China will include a 400,000-square-foot cGMP cleanroom and a total bioreactor capacity of 80,000-liters in separate cleanroom suites. The goal is to produce five commercial products simultaneously and fulfill the needs of chemistry, manufacturing, and controls (CMC) for over 12 programs in clinical trials.

“The planned facilities, with a total bioreactor capacity of 80,000-liters, will provide sufficient quantities of drug substances and drug products to support preclinical and clinical development and ultimately commercial launch”, said Dr. Gui-Dong Zhu, CEO of Sparx.

 

Targeting Solid Tumors with Multi-Specific Antibody

Sparx develops multi-specific antibody and antibody-drug conjugate (ADC) discovery platforms to target solid tumors such as gastric and colon cancer. 

Currently, the firm has three first-in-class candidates in the preclinical stage and three candidates ready for an investigational new drug (IND) application. Its R&D power has also attracted Eli Lilly’s distinguished research fellow, Dr. Victor Wroblewski, to join as the senior VP and the head of biology.

Aside from the expected plant in Yangzhou Economic Zone, Sparx has in-house facilities in Chicago and China to manufacture clinical and commercial drug substances but feels the need to expand as they couldn’t meet the development needs for antibody production, especially commercial use.

Related Article: Gilead’s Yescarta Becomes First CAR-T Therapy to Score Regulatory Approval in China

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology
2023-03-14
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
First Made-in-Singapore Antibody-Drug Conjugate Approved to Enter Clinical Trials
2023-01-09
LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top